T1	p 93 98	human
T2	p 128 187	patients with hemodynamically decompensated heart failure .
T3	p 282 311	decompensated cardiac failure
T4	p 424 448	in human heart failure .
T5	p 540 585	16 decompensated heart failure patients in an
T6	p 779 799	microgram/kg/min [ n
T7	p 802 804	12
T8	p 960 984	group were excluded from
T9	p 1550 1558	patients
T10	p 1564 1573	resistant
T11	p 1958 1987	decompensated heart failure .
T12	i 223 230	peptide
T13	i 233 239	hBNP )
T14	i 388 392	hBNP
T15	i 486 512	continuous 4-hour infusion
T16	i 516 520	hBNP
T17	i 625 643	placebo-controlled
T18	i 735 744	placebo [
T19	i 760 773	hBNP 0.025 or
T20	i 779 795	microgram/kg/min
T21	i 928 934	hBNP .
T22	i 1092 1117	pulmonary capillary wedge
T23	i 1323 1327	hBNP
T24	i 1425 1432	placebo
T25	i 1657 1661	hBNP
T26	i 1736 1740	hBNP
T27	i 1882 1885	. 4
T28	i 1888 1892	hBNP
T29	o 15 62	hemodynamic , neurohormonal , and renal effects
T30	o 105 124	natriuretic peptide
T31	o 211 232	natriuretic peptide (
T32	o 328 384	systemic hemodynamic , neurohormonal , and renal effects
T33	o 830 853	. Urinary volume losses
T34	o 1009 1030	adverse events . hBNP
T35	o 1066 1126	right atrial pressure and pulmonary capillary wedge pressure
T36	o 1207 1235	systemic vascular resistance
T37	o 1356 1369	cardiac index
T38	o 1397 1412	in heart rate .
T39	o 1435 1508	hBNP decreased plasma norepinephrine and aldosterone . Renal hemodynamics
T40	o 1634 1653	hemodynamic effects
T41	o 1681 1731	cardiac preload and systemic vascular resistance .
T42	o 1755 1769	cardiac output
T43	o 1778 1788	increasing
T44	o 1795 1860	rate . 3 ) Plasma norepinephrine and aldosterone levels decreased